Carotid Intima Media Thickness (CIMT) in Epistaxis

Atherosclerosis Clinical Trial

Official title:

Carotid Intima Media Thickness in Patients With Epistaxis: a Surrogate Marker for Generalised Atherosclerosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03092973
• Other study ID #: CIMT in Epistaxis
• Status: Completed
• Phase: N/A
• First received: March 22, 2017
• Last updated: October 26, 2017
• Start date: December 1, 2016
• Est. completion date: June 30, 2017

Study information

• Verified date: October 2017
• Source: University of Zurich
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Epistaxis is a very frequent emergency among adults and often needs specialised treatment in an ENT-department. Among others, atherosclerosis is often named as a reason for an increased risk for Epistaxis. To evaluate whether or not this is the case, the investigators examined the carotid intima media thickness via ultrasound in patients who were treated in the ENT-department of the University Hospital of Zurich.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 82
• Est. completion date: June 30, 2017
• Est. primary completion date: June 30, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• active or very recently active anterior or posterior epistaxis

• at least 18 years old

Exclusion Criteria:

• posttraumatic or postoperative epistaxis

Related Conditions & MeSH terms

• Atherosclerosis
• Epistaxis

Intervention

Diagnostic Test:
• Ultrasound

Locations

Country	Name	City	State
Switzerland	University Hospital of Zurich	Zurich	ZH

Sponsors (1)

Lead Sponsor	Collaborator
University of Zurich

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Carotid Intima Media Thickness in Epistaxis vs. Controls		June 2017